Nasal compliance measurement for diagnosis of idiopathic non‐allergic rhinitis: A prospective case‐controlled study of 63 patients

• Published in: Clinical otolaryngology 2018-02, Vol.43 (1), p.328-332
• Main Authors: Louis, B., Bequignon, E., Devars du Mayne, M., Zerah‐Lancner, F., Larger, C., Isabey, D., Coste, A., Papon, J.F.
• Format: Article
• Language: English
• Subjects: Allergic rhinitis; Human health and pathology; Life Sciences; Pulmonology and respiratory tract; Rhinitis; Sensory Organs
• ISSN: 1749-4478; 0307-7772; 1749-4486; 1365-2273
• DOI: 10.1111/coa.12935

Monoclonal antibodies (mAbs) are promising therapies to treat airway chronic inflammatory disease (asthma or nasal polyps). To date, no study has specifically assessed, in vitro, the potential function of neonatal Fc receptor (FcRn) in IgG transcytosis through the human nasal airway epithelium. The objective of this study was to report the in vitro expression and function of FcRn in nasal human epithelium. FcRn expression was studied in an air–liquid interface (ALI) primary culture model of human nasal epithelial cells (HNEC) from polyps. FcRn expression was characterized by quantitative RT-PCR, western blot, and immunolabeling. The ability of HNECs to support mAb transcytosis via FcRn was assessed by transcytosis assay. This study demonstrates the expression of FcRn mRNA and protein in HNEC. We report a high expression of FcRn in the cytosol of ciliated, mucus, and basal cells by immunohistochemistry with a higher level of FcRn proteins in differentiated HNEC. We also proved in vitro transepithelial delivery of an IgG1 therapeutic mAb with a dose–response curve. This is the first time that FcRn expression and mAb transcytosis has been shown in a model of human nasal respiratory epithelium in vitro. This study is a prerequisite for FcRn-dependent nasal administration of mAbs.